共 50 条
- [41] Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer (MCRC).JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157SMeyerhardt, J. A.Stuart, K.Zhu, A.Fuchs, C.Bhargava, P.Earle, C.Blaszkowsky, L.Lawrence, C.Battu, S.Ryan, D. P.
- [42] Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC).JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 265S - 265SMeyerhardt, JAXhu, AEnzinger, PCRyan, DPClark, JWKulke, MHMichelini, AVincitore, MThomas, AFuchs, CS
- [43] Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II studyJOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S16 - S16Ahn, Myung-JuLim, Sung HeeSun, Jong -MuChoi, Yoon-LaKim, Hye RyunAhn, Soo-minLee, Se-HoonAhn, Jin SeokPark, KeunchilKim, Joo HangCho, Byoung Chul
- [44] A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Piha-Paul, Sarina AnneHierro, CintaFunk, Jens OliverGourlay, StevenSmith, PatrickVenetsanakos, EleniMeric-Bernstam, FundaTabernero, Josep
- [45] A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Piha-Paul, Sarina AnneHierro, CintaBoni, ValentinaMoreno, VictorHahn, Noah M.Bitting, Rhonda L.Bauer, Todd MichaelAggarwal, Rahul RajGourlay, StevenSmith, PatrickVenetsanakos, EleniMeric-Bernstam, FundaBrameld, KenKarr, DaneTabernero, Josep
- [46] Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single-arm phase II trialEXPERIMENTAL DERMATOLOGY, 2024, 33 (01)Maeda, TakuyaYanagi, TerukiTokuchi, KeikoFunakoshi, TakeruHorie, NaoIsoe, ToshiyukiIto, Yoichi M.Sato, NorihiroUjiie, Hideyuki
- [47] A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancerBMC CANCER, 2019, 19 (01)Strickler, John H.Rushing, Christel N.Niedzwiecki, DonnaMcLeod, AbigailAltomare, IvyUronis, Hope E.Hsu, S. DavidZafar, S. YousufMorse, Michael A.Chang, David Z.Wells, James L.Blackwell, Kimberly L.Marcom, P. KellyArrowood, ChristyBolch, EmilyHaley, SherriRangwala, Fatima A.Hatch, Ace J.Nixon, Andrew B.Hurwitz, Herbert, I
- [48] A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancerBMC Cancer, 19John H. StricklerChristel N. RushingDonna NiedzwieckiAbigail McLeodIvy AltomareHope E. UronisS. David HsuS. Yousuf ZafarMichael A. MorseDavid Z. ChangJames L. WellsKimberly L. BlackwellP. Kelly MarcomChristy ArrowoodEmily BolchSherri HaleyFatima A. RangwalaAce J. HatchAndrew B. NixonHerbert I. Hurwitz
- [49] Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II multicenter single-arm study and exploratory biomarker analysisJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Xu, TingWang, XichengXin, YingWang, ZhenghangWang, YakunQi, ChangsongLiu, DanLi, YanyanGong, JifangLi, JianHuang, DepeiShen, Lin
- [50] A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Angevin, E.Gruenwald, V.Ravaud, A.Castellano, D. E.Lin, C. C.Gschwend, J. E.Harzstark, A. L.Chang, J.Wang, Y.Shi, M. M.Escudier, B. J.